PDF(Pubmed)
Abstract：
UNASSIGNED: Recent studies have shown that the fibrinogen to albumin ratio (FAR) is closely related to the prognosis of various cancers. The aim of this systematic review and meta-analysis was to investigate the prognostic value of FAR in malignancies based on the available evidence.
UNASSIGNED: To systematically search the Cochrane Library, Embase, PubMed, Google Scholar, Baidu scholars, CNKI and VIP databases for relevant studies published before April 1, 2022, and to evaluate the fibrinogen-to-albumin ratio (FAR) and survival of patients with malignant tumors through a meta-analysis relationship between the results. Results. This meta-analysis included 19 eligible studies involving 5926 cancer patients. We found that high FAR was associated with poor overall survival (HR=2.25, 95%CI 1.86-2.74, p<0.001), recurrence-free survival (HR=2.29, 95%CI 1.91-2.76, P<0.001), progression-free survival (HR: 2.10, 95%CI 1.58-2.79, p<0.001), disease-free survival (HR=1.52, 95%CI 1.17-1.96, p=0.001), and time to recurrence (HR: 1.555, 95%CI 1.031-2.346, P=0.035) was significantly correlated.
UNASSIGNED: High FAR is significantly associated with poor clinical outcomes in cancer, suggesting that it may be an important predictor of prognosis in patients with malignancies.
UNASSIGNED: To systematically search the Cochrane Library, Embase, PubMed, Google Scholar, Baidu scholars, CNKI and VIP databases for relevant studies published before April 1, 2022, and to evaluate the fibrinogen-to-albumin ratio (FAR) and survival of patients with malignant tumors through a meta-analysis relationship between the results. Results. This meta-analysis included 19 eligible studies involving 5926 cancer patients. We found that high FAR was associated with poor overall survival (HR=2.25, 95%CI 1.86-2.74, p<0.001), recurrence-free survival (HR=2.29, 95%CI 1.91-2.76, P<0.001), progression-free survival (HR: 2.10, 95%CI 1.58-2.79, p<0.001), disease-free survival (HR=1.52, 95%CI 1.17-1.96, p=0.001), and time to recurrence (HR: 1.555, 95%CI 1.031-2.346, P=0.035) was significantly correlated.
UNASSIGNED: High FAR is significantly associated with poor clinical outcomes in cancer, suggesting that it may be an important predictor of prognosis in patients with malignancies.
摘要：
UNASSIGNED：最近的研究表明，纤维蛋白原与白蛋白之比（FAR）与各种癌症的预后密切相关。本系统综述和荟萃分析的目的是根据现有证据研究FAR在恶性肿瘤中的预后价值。
未经评估：要系统地搜索Cochrane图书馆，Embase,PubMed,谷歌学者，百度学者，针对2022年4月1日前发表的相关研究CNKI和VIP数据库，并通过meta分析结果评价了纤维蛋白原与白蛋白比值(FAR)与恶性肿瘤患者生存率之间的关系。结果。这项荟萃分析包括19项符合条件的研究，涉及5926名癌症患者。我们发现高FAR与低总生存率相关(HR=2.25,95CI1.86-2.74,p<0.001),无复发生存率（HR=2.29，95CI1.91-2.76，P<0.001），无进展生存期（HR：2.10，95CI1.58-2.79，p<0.001），无病生存率（HR=1.52，95CI1.17-1.96，p=0.001），与复发时间（HR：1.555，95CI1.031-2.346，P=0.035）显着相关。
未经证实：高FAR与癌症临床预后不良显著相关，提示它可能是恶性肿瘤患者预后的重要预测因子。
未经评估：要系统地搜索Cochrane图书馆，Embase,PubMed,谷歌学者，百度学者，针对2022年4月1日前发表的相关研究CNKI和VIP数据库，并通过meta分析结果评价了纤维蛋白原与白蛋白比值(FAR)与恶性肿瘤患者生存率之间的关系。结果。这项荟萃分析包括19项符合条件的研究，涉及5926名癌症患者。我们发现高FAR与低总生存率相关(HR=2.25,95CI1.86-2.74,p<0.001),无复发生存率（HR=2.29，95CI1.91-2.76，P<0.001），无进展生存期（HR：2.10，95CI1.58-2.79，p<0.001），无病生存率（HR=1.52，95CI1.17-1.96，p=0.001），与复发时间（HR：1.555，95CI1.031-2.346，P=0.035）显着相关。
未经证实：高FAR与癌症临床预后不良显著相关，提示它可能是恶性肿瘤患者预后的重要预测因子。
